Research Papers:

Oligomer procyanidins (F2) repress HIF-1α expression in human U87 glioma cells by inhibiting the EGFR/ AKT/mTOR and MAPK/ERK1/2 signaling pathways in vitro and in vivo

Hong-Li Zheng, Li-Hui Wang, Bao-Shan Sun, Yi Li, Jing-Yu Yang and Chun-Fu Wu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:85252-85262. https://doi.org/10.18632/oncotarget.19654

Metrics: PDF 1511 views  |   HTML 2284 views  |   ?  


Hong-Li Zheng1,3, Li-Hui Wang1,3, Bao-Shan Sun2,4, Yi Li1,3, Jing-Yu Yang1,3 and Chun-Fu Wu1,3

1Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, P.R. China

2Department of Enology, Shenyang Pharmaceutical University, Shenyang, P.R. China

3Benxi Institute of Pharmaceutical Research, Shenyang Pharmaceutical University, Benxi, P.R. China

4Viticultural and Enological Research Unit-National Institute for Agricultural and Veterinary Research, Dois Portos, Portugal

Correspondence to:

Chun-Fu Wu, email: [email protected]

Jing-Yu Yang, email: [email protected]

Keywords: F2, HIF-1α, angiogenesis, invasion, U87 glioma cell

Received: September 13, 2016    Accepted: May 31, 2017    Published: July 28, 2017


Hypoxia-inducible factor-1 (HIF-1) is over-expressed in gliomas and has become one of the most compelling tumor targets. In this study, we found that oligomer procyanidins (F2) can suppress the expressions of HIF-1α and its target genes in U87 cells, and also down-regulate the EGFR/PI3K/AKT/mTOR and MAPK/ERK1/2 pathways in vitro and in vivo. Furthermore, hypoxia-induced formation of tubular structures by human umbilical vascular endothelial cells and the migration and invasion of U87 cells could be inhibited by F2 in a HIF-1 dependent manner. Moreover, in a U87 xenograft tumor model, F2 significantly reduced intra-tumor vessel density and cell proliferation and finally retarded tumor growth, indicating that F2 may be a potential HIF-1 inhibitor and serve as one of candidates for glioma therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19654